Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.52 |
| ▸ | FABP7 | O15540 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5497604 | 0.87 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL10261416 | 0.86 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29708199 | 0.85 | ALDH1A1 (0.54) | KMT2AFABP5FABP7EPHX2 | |
| SCHEMBL3920318 | 0.84 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL8474153 | 0.84 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL3623157 | 0.84 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL4839280 | 0.84 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29397975 | 0.84 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7268313 | 0.84 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14407142 | 0.84 | KMT2A (0.52) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912645-B2 | Lipopeptide compounds for the treatment of pain disorders | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2024-02-27 | — | — | US | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-11793881-B2 | Polyethylene glycol conjugate medicament, preparation method therefor and use thereof | Chongqing Upgra Biotechnology Co., Ltd. (CN) | 2023-10-24 | — | — | US | disclosed |
| US-20230303619-A1 | DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230129258-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LIMITED (GB) | 2023-04-27 | — | — | US | disclosed |
| US-20180215782-A1 | PEPTIDE SYNTHESIS METHOD | JITSUBO CO., LTD. (JP) | 2018-08-02 | — | — | US | disclosed |
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | ONYX THERAPEUTICS INC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170360668-A1 | USE OF ESTER DERIVATIVE OF TRYPTOPHAN AS DEODORANT AND/OR PERFUME AGENT | L'OREAL (FR) | 2017-12-21 | — | — | US | disclosed |
| US-20170246326-A1 | Modular Imaging Agents Containing Amino Acids and Peptides | ROCHESTER INSTITUTE OF TECHNOLOGY (US) | 2017-08-31 | — | — | US | disclosed |
| US-20100311827-A1 | Chlorogenic acid derivatives and their use as anti-fungal agents | GENESIS GROUP INC. (CA) | 2010-12-09 | — | — | US | disclosed |
| US-7642285-B2 | Compounds and methods for modulating communication and virulence in quorum sensing bacteria | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080287346-A1 | Bioactive peptides | SVENDSEN JOHN SIGURD | 2008-11-20 | — | — | US | disclosed |
| US-7417030-B2 | Indazole peptidomimetics as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7414105-B2 | Peptide dimer bonded to polyethylene glycol through amide groups; insufficient or defective red blood cell production | AFFYMAX, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-7312306-B2 | Substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070286846-A1 | Novel methods for ester detoxication | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2007-12-13 | — | — | US | disclosed |
| US-7256253-B2 | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components | CONJUCHEM BIOTECHNOLOGIES INC. (CA) | 2007-08-14 | — | — | US | disclosed |
| US-20070032408-A1 | Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180215782-A1 | PEPTIDE SYNTHESIS METHOD | NPPA, PEPD, PTMS | KMT2A 4306/4885FABP5 1296/4885FABP7 800/4885 |
| US-20080287346-A1 | Bioactive peptides | VIP, NGLY1, IAPP | KMT2A 4638/4885FABP5 755/4885FABP7 845/4885 |
| US-20180170962-A1 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION | PSMB1, PSMB9, PSMB3 | KMT2A 2447/4885FABP5 4544/4885FABP7 4149/4885 |
| US-11912645-B2 | Lipopeptide compounds for the treatment of pain disorders | VIP, FABP2, TRPV1 | KMT2A 4623/4885FABP5 115/4885FABP7 36/4885 |
| US-20100311827-A1 | Chlorogenic acid derivatives and their use as anti-fungal agents | ERG28, CYP51A1, ETF1 | KMT2A 2667/4885FABP5 1965/4885FABP7 1824/4885 |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | ARG2, NLN, OAT | KMT2A 4069/4885FABP5 3390/4885FABP7 435/4885 |
| US-11793881-B2 | Polyethylene glycol conjugate medicament, preparation method therefor and use thereof | SLC10A1, SLC10A2, NOTUM | KMT2A 2951/4885FABP5 2747/4885FABP7 2014/4885 |
| US-20170360668-A1 | USE OF ESTER DERIVATIVE OF TRYPTOPHAN AS DEODORANT AND/OR PERFUME AGENT | TPH1, TPH2, TDO2 | KMT2A 3579/4885FABP5 240/4885FABP7 212/4885 |
| US-20230303619-A1 | DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND | VIP, PEPD, MLN | KMT2A 1449/4885FABP5 1921/4885FABP7 2202/4885 |
| US-20070032408-A1 | Novel spacer moiety for poly (ethylene glycol) modified peptide based compounds | NGLY1, YWHAZ, PAM | KMT2A 4258/4885FABP5 2973/4885FABP7 2026/4885 |
| US-20070286846-A1 | Novel methods for ester detoxication | CES2, BCHE, ACHE | KMT2A 2377/4885FABP5 565/4885FABP7 122/4885 |
| US-20230129258-A1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | TAP1, TIMCC, CD81 | KMT2A 2917/4885FABP5 1317/4885FABP7 1528/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | KMT2A 3991/4885FABP5 3373/4885FABP7 2527/4885 |
| US-20170246326-A1 | Modular Imaging Agents Containing Amino Acids and Peptides | SLC43A1, TAP1, TFIP11 | KMT2A 1561/4885FABP5 352/4885FABP7 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.